Project Grant R01DA062669
- The University of Washington was awarded a $149,284 Project Grant by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate the role of specific subpopulations of prefrontal cortex pyramidal neurons in regulating drug-seeking behavior. The research aims to elucidate the factors that predispose individuals to addiction and confer vulnerability to relapse, with the goal of advancing understanding of the functional roles of...
- Federal Project Grant Summary Duke University's Office of Research Administration received a $872,100 Project Grant award (September 30, 2025 – May 31, 2030) from the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct basic neuroscience research investigating the epigenetic mechanisms underlying cocaine addiction. The research will utilize mouse models exposed to cocaine in a conditioned place preference paradigm to identify and...
- Federal Project Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded a $181,092 Project Grant to Icahn School of Medicine at Mount Sinai effective May 1, 2026, through April 30, 2028, under the Drug Use and Addiction Research Programs (CFDA 93.279). This K99/R00 career development award supports fundamental neuroscience research investigating dopamine receptor type 2 (D2)-expressing neurons in the ventral hippocampus and their role in cocaine relapse vulnerability. The...
- This $2.275 million Project Grant awarded by the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279) supports a research initiative at Vanderbilt University beginning July 1, 2025, and extending through March 31, 2030. The project, titled "Molecular Determinants of Ensemble Recruitment by Drugs of Abuse," investigates how cocaine-activated neuronal ensembles are recruited and maintained within the nucleus accumbens—a key reward-related...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded The Children's Hospital of Philadelphia Research Institute a $534,000 Project Grant effective September 1, 2025, through May 31, 2030, under the Drug Use and Addiction Research Programs (CFDA 93.279). This research initiative investigates the lifespan effects of prenatal and perinatal opioid exposure on the brain's metabolic-epigenetic axis. The project addresses a critical gap in neuroprotective treatment...
- Federal Project Grant Award Summary Boston University Medical Campus received a $109,076 Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded January 9, 2026, with completion targeted for July 31, 2029. The grant supports basic neuroscience research investigating the role of G alpha Z (GAZ) protein in mediating behavioral responses to opioids. The research aims to elucidate how GAZ signaling in specific brain...
- Federal Project Grant Award Summary The National Institute on Drug Abuse (NIDA), under its Drug Use and Addiction Research Programs (CFDA 93.279), awarded the Regents of the University of California, San Francisco $1,620,883 on July 1, 2025, to support research investigating the neural mechanisms underlying sudden insight learning in cue-reward associations. This research project, scheduled for completion on March 31, 2030, delivers fundamental neuroscience research services examining how...
- Federal Project Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded $4.63 million through its Drug Use and Addiction Research Programs (CFDA 93.279) to The Research Foundation for the State University of New York/SUNY Downstate Health Sciences University on September 30, 2025, for a longitudinal research project extending through June 30, 2029. This project grant supports multidisciplinary research examining neighborhood conditions, neural circuits, and substance use...
- Federal Project Grant Award Summary New York University has been awarded $201,250 by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) for a two-year project period from June 1, 2025, through May 31, 2027. This Project Grant supports basic neuroscience research investigating the synaptic organization of cholinergic interneurons in the nucleus accumbens, a brain region critical to motivated behaviors and implicated in substance use...
- Federal Grant Award Summary The Children's Hospital of Philadelphia Research Institute received a $549,436 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), effective June 16, 2025, with a completion date of January 31, 2027. This two-year research initiative investigates the neural mechanisms underlying fentanyl-linked context memories with the objective of developing novel therapeutic interventions to...
This $800,131 Project Grant award from the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279) supports a five-year research initiative (May 1, 2026 – February 28, 2031) at Boston Children's Hospital to elucidate the functions and mechanisms of a molecularly defined prefrontal cortex (PFC) neuron subtype in drug addiction. The research addresses a critical gap in addiction treatment by investigating how POU3F1-positive neurons in the PFC regulate addictive behaviors through their projections to the midbrain periaqueductal gray region. Leveraging advanced molecular techniques including single-cell RNA sequencing and spatial transcromics, the investigator team will characterize the molecular composition and anatomical organization of PFC neuronal subtypes and establish mechanistic links between POU3F1+ neuronal circuits and cocaine-seeking behavior using established intravenous cocaine self-administration mouse models. The research outcomes will deliver new knowledge regarding neural circuit mechanisms underlying addiction pathophysiology and identify potential targeted intervention points for developing more effective addiction treatments. By decoding PFC heterogeneity and demonstrating that chemogenetic activation of POU3F1+ neurons reduces drug-seeking behavior, this project contributes to the Drug Use and Addiction Research Programs' objective of advancing fundamental neuroscience understanding to support prevention, diagnosis, and treatment development for substance use disorders.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $800.1k | 4/28/26 |